Avalo Therapeutics, Inc. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Avalo amended employment agreements for Paul Varki and Jennifer Riley, effective June 12, 2026. Changes include: (1) Without-Cause termination now provides 12 months base salary continuation plus COBRA, with full vesting of pre-amendment options; (2) Change-of-Control termination (within 3 months before to 12 months after) provides 1.0x base + 1.0x target bonus (lump sum), plus full acceleration of all unvested time-based equity, plus COBRA; (3) Added Section 280G tax-cutback provisions. Specific dollar amounts and equity values not disclosed in amendment text.
Why this rating
Executive severance amendments are routine governance; no equity values stated. At $53.7M market cap, immaterial unless executives hold substantial equity or termination occurs imminently—neither signaled here.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.